Overview

* ProKidney ended Q3 2025 with $272 mln in cash, supporting operations into mid-2027

Outlook

* Company expects cash to support operations into mid-2027

Result Drivers

* R&D EXPENSES - Decrease in R&D expenses due to winding down of completed or terminated trials

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $38.76

Operatin mln

g

Expenses

Q3 -$38.54

Operatin mln

g Income

Q3 -$35.28

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Prokidney Corp ( PROK ) is $6.50, about 55.5% above its November 7 closing price of $2.89

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)